Overview

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Status:
Not yet recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

This phase Ib/II tests the safety, side effects, and best dose of icosapent ethyl in combination with dasatinib and whether they work in treating patients with triple-negative inflammatory breast cancer that has spread to other places in the body (metastatic). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Icosapent ethyl is a highly purified omega-3 fatty acid that may slow tumor growth and disease progression. Giving dasatinib and icosapent ethyl may help shrink tumors in patients with inflammatory breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Dasatinib
Eicosapentaenoic acid ethyl ester